SEC filings
Eli Lilly (LLY)
Recent filings Eli Lilly made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000059478All filings on SEC.gov
10-QQuarterly report
Quarterly report
Eli Lilly's third-quarter 2026 revenue rose 39% to $24.4 billion and net income rose 16% to $6.45 billion, driven by Mounjaro and Zepbound. The company also said the FDA approved insulin efsitora alfa for type 2 diabetes and orforglipron…
8-KCurrent report
Results of Operations and Financial Condition
Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year on demand for Mounjaro and Zepbound, and raised its full-year 2026 revenue guidance midpoint by $5.5 billion to a range of $91.0–$92.0 billion. …
10-QQuarterly report
Quarterly report
Eli Lilly reported second-quarter 2026 revenue of $22.97 billion, up 48% from a year earlier, and net income of $7.10 billion ($7.94 per diluted share), growth it attributed to higher volume partially offset by lower realized prices…
8-KCurrent report
Results of Operations and Financial Condition
Eli Lilly reported second-quarter 2026 revenue of $23.0 billion, up 48% from a year earlier, raised full-year 2026 revenue guidance to $85–87 billion, and posted reported EPS of $7.94 (up 26%) and non-GAAP EPS of $8.38 (up 33%), both…
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Eli Lilly in Readster
Add Eli Lilly to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.